ERIS · Healthcare · Drug Manufacturers - Specialty & Generic
Composite scorecard: 41/100 — Quality 60 · Valuation 17 · Growth 50 · Momentum 21
| Share price | ₹1,463.30 |
| Market cap | ₹18,502 Cr |
| P/E ratio | 43.1 |
| P/B ratio | 6.0 |
| ROE | 12.5% |
| ROCE | 12.7% |
| Dividend yield | 0.97% |
| Book value | ₹226.84 |
| Year | Sales | Net profit | OPM |
|---|---|---|---|
| 2026 | ₹3,129 Cr | ₹648 Cr | 36.0% |
| 2025 | ₹2,894 Cr | ₹375 Cr | 35.0% |
| 2024 | ₹2,009 Cr | ₹397 Cr | 34.0% |
| 2023 | ₹1,685 Cr | ₹374 Cr | 32.0% |
| 2022 | ₹1,347 Cr | ₹406 Cr | 36.0% |
Eris Lifesciences Limited, together with its subsidiaries, provides domestic branded formulations for chronic and sub-chronic therapies in India and internationally. The company offers various branded formulations in various therapeutic areas, such as antidiabetes, cardiovascular, nutrition, dermatology, neuroscience, gynecology, nephrology, and oncology, as well as central nervous system, women's health, and vitamins/minerals/nutrients. It also provides patient care services, including ambulatory blood pressure measurement, ambulatory electrocardiogram measurement, continuous glucose monitor